Prioritisation of potential drug targets against Bartonella bacilliformis by an integrative in-silico approach

Abstract

BACKGROUND  Carrion’s disease (CD) is a neglected biphasic illness caused by Bartonella bacilliformis, a Gram-negative bacteria found in the Andean valleys. The spread of resistant strains underlines the need for novel antimicrobials against B. bacilliformis and related bacterial pathogens.

OBJECTIVE  The main aim of this study was to integrate genomic-scale data to shortlist a set of proteins that could serve as attractive targets for new antimicrobial discovery to combat B. bacilliformis.

METHODS  We performed a multidimensional genomic scale analysis of potential and relevant targets which includes structural druggability, metabolic analysis and essentiality criteria to select proteins with attractive features for drug discovery.

FINDINGS  We shortlisted seventeen relevant proteins to develop new drugs against the causative agent of Carrion’s disease. Particularly, the protein products of fabI, folA, aroA, trmFO, uppP and murE genes, meet an important number of desirable features that make them attractive targets for new drug development. This data compendium is freely available as a web server (http://target.sbg.qb.fcen.uba.ar/).

MAIN CONCLUSION  This work represents an effort to reduce the costs in the first phases of B. bacilliformis drug discovery.

Key words:
Bartonella bacilliformis; drug targets; structurome; metabolic networks; Carrion’s disease